2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

2:30PM-4:00PM: Abstract Number: 2794

Peptidylarginine Deiminases Are Required for Normal Immunoglobulin G Half-Life

5T085 ACR Abstract: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (2791–2796)

2:30PM-4:00PM: Abstract Number: 2848

Racial Disparities in Utilization of Knee Replacement: Data from the Osteoarthritis Initiative

5T099 ARHP Abstract: Clinical Aspects & Outcomes Research–ARHP II (2844–2849)

2:30PM-4:00PM: Abstract Number: 2825

Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab

5T089 ACR Abstract: RA–Treatments IV: Strategy (2820–2825)

2:30PM-4:00PM: Abstract Number: 2797

Regulation of Autoimmune T Cells By the Co-Receptors CD28 and PD-1

5T092 ACR Abstract: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2797–2801)

2:30PM-4:00PM: Abstract Number: 2827

Remission Targets and Prevention of Subclinical Atherosclerosis in Psoriatic Arthritis- Which Target Should We Choose?

5T091 ACR Abstract: Spondyloarthritis Incl PsA–Clinical IV: Comorbid/Related Conditions(2826–2831)

2:30PM-4:00PM: Abstract Number: 2802

Risk of Ischemic Stroke in Veterans with Systemic Sclerosis: A Nationwide Cohort Study

5T086 ACR Abstract: Epidemiology & Pub Health III: SLE & SSc, Big Data & Large Cohorts (2802–2807)

2:30PM-4:00PM: Abstract Number: 2849

Risk of Obstructive Sleep Apnea in Rheumatoid Arthritis

5T099 ARHP Abstract: Clinical Aspects & Outcomes Research–ARHP II (2844–2849)

2:30PM-4:00PM: Abstract Number: 2813

Risk of Venous Thromboembolism with Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Trials

5T087 ACR Abstract: Osteoporosis & Metabolic Bone Disease–Basic & Clinical Science (2808–2813)

2:30PM-4:00PM: Abstract Number: 2796

Sex-Based Differences Control ABC Function in Swef-Deficient Mice

5T085 ACR Abstract: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (2791–2796)

2:30PM-4:00PM: Abstract Number: 2822

Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis

5T089 ACR Abstract: RA–Treatments IV: Strategy (2820–2825)

2:30PM-4:00PM: Abstract Number: 2799

Sjogren’s Syndrome Minor Salivary Gland CD4+ T Cells Associate with Oral Disease Features and Have a T Follicular Helper-like Transcriptional Profile

5T092 ACR Abstract: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2797–2801)

2:30PM-4:00PM: Abstract Number: 2809

Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed

5T087 ACR Abstract: Osteoporosis & Metabolic Bone Disease–Basic & Clinical Science (2808–2813)

2:30PM-4:00PM: Abstract Number: 2820

Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial

5T089 ACR Abstract: RA–Treatments IV: Strategy (2820–2825)

2:30PM-4:00PM: Abstract Number: 2830

Synovitis in Psoriatic Arthritis and Seronegative Rheumatoid Arthritis: Differential Histological Features

5T091 ACR Abstract: Spondyloarthritis Incl PsA–Clinical IV: Comorbid/Related Conditions(2826–2831)

2:30PM-4:00PM: Abstract Number: 2808

T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial

5T087 ACR Abstract: Osteoporosis & Metabolic Bone Disease–Basic & Clinical Science (2808–2813)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].